JPRN-jRCT2080225162已完成1 期
A Phase I/II, Multicenter, Open-Label, Nonrandomized Study to Evaluate the Tolerability and Safety of ASTX660 and the Efficacy at the Recommended Dose of ASTX660 in Patients With Relapsed or Refractory T-Cell Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients with T-cell lymphoma with histological diagnosis based on WHO classification (2017)
- •2) Patients with evaluable lesions.
- •3) Patients with ECOG PS score of 0 or 1.
- •4) Patients with adequate organ functions as shown below.
- •a) AST and ALT 2.0xULN or less (3.0xULN or less if liver infiltration is present)
- •b) Total bilirubin 1.5xULN or less
- •c) ANC 1,000/mm3 or more (750/mm3 or more if bone marrow infiltration is present)
- •d) Platelet count 50,000/mm3 or more (25,000/mm3 or more if bone marrow infiltration is present)
- •e) Serum creatinine 1.5xULN or less or creatinine clearance 50 mL/min or more
- •f) Amylase and lipase 1.0xULN or less
排除标准
- •1) Patients with active infection requiring treatment with antibiotics, antifungals, or antivirals
- •2) Patients with heart disease that meets the followings:
- •a) LVEF of < 50% by echocardiography or MUGA scan
- •b) Congestive heart failure (NYHA classification 3 or 4)
- •c) Uncontrolled heart disease including unstable angina pectoris or hypertension considered to require hospitalization within last 3 months (90 days)
- •d) Complete left bundle branch block, 3 degree (complete) atrioventricular block, use of pacemaker, history or complication of poorly controlled arrhythmia requiring treatment
- •e) History or complication of long QT syndrome
- •f) History or complication of ventricular arrhythmia requiring active treatment
- •g) Corrected QT interval of 470 or more msec based on 12-lead ECG performed at the screening
- •h) Concern on increased cardiac risk by participating in the study based on medical judgment
- •3) Patients receiving the following treatment for the primary disease prior to the initial dose of study drug
- •a) Chemotherapy or radiotherapy within last 3 weeks
- •b) Skin directed therapy including local treatment or phototherapy within last 3 weeks
- •c) Treatment with monoclonal antibody within last 4 weeks
- •d) Treatment with other study drugs or study treatment within last 3 weeks or 5 half-lives, whichever is longer
- •4) Patients with prior allogeneic stem cell transplantation, or autologous stem cell transplantation within 14 weeks prior to the day of initial dose of study drug
- •5) Patients who have received corticosteroids at a dose exceeding a prednisone equivalent dose of 10 mg/day within 3 weeks prior to the initial dose of study drug.
- •6) Patients with Inadequately controlled diabetes mellitus
研究者
相似试验
进行中（未招募）
1 期
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHPatients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 18.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003717-29-ESAstraZeneca AB240
进行中（未招募）
1 期
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHPatients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 18.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003717-29-FRAstraZeneca AB240
进行中（未招募）
1 期
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHPatients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 18.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003717-29-CZAstraZeneca AB240
进行中（未招募）
1 期
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHEUCTR2014-003717-29-BEAstraZeneca AB240
进行中（未招募）
1 期
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHPatients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003717-29-DEAstraZeneca AB240